Neuron-specific enolase and its mRNA are highly expressed in large congenital nevi: A study using immunocytochemistry, biochemical assay, and in situ hybridization
- 26 Downloads
The malignant transformation of congenital nevocellular nevi, both large and small, is controversial and presents problems in management. The size of the lesion is taken to indicate potential malignant transformation, but this is an arbitrary scale. A more reliable biological indicator is needed to help predict the lesions at risk. Following the localization of neuron-specific enolase to most cells of the diffuse neuroendocrine system and their neoplasms (including benign and malignant melanocytic lesions), it has been suggested that its level is related to tumor activity. In a prospective trial, the presence of neuron-specific enolase immunoreactivity, its concentration, and gene expression in nevus cells were studied in 31 congenital melanocytic nevi of various sizes (1.5 cm to bathing trunk) using immunocytochemistry, biochemical assay, and in situ hybridization. Twenty-five of the 31 congenital nevi were immunoreactive to neuron-specific enolase antiserum, with stronger immunostaining in the larger lesions. There is an apparent linear relationship between the size of the nevi and the level of neuron-specific enolase (expressed as nanograms per milligram protein). Neuron-specific enolase mRNA was highly expressed in most of the large congenital nevi (>15 cm in diameter), as revealed by autoradiography following in situ hybridization. Our results show that neuron-specific enolase and its mRNA are expressed to a greater extent in large congenital nevi compared with the smaller lesions. This might prove to be a useful indicator of those lesions at risk of malignant transformation.
KeywordscRNA Probe Nevus Cell Congenital Melanocytic Nevus Congenital Nevus Diffuse Neuroendocrine System
Unable to display preview. Download preview PDF.
- Carimele, D., Torsellini, M., Serrif, F. (1977) Comportamento degli enzimi del metabolismo energetico mel melanoma maligno e nelle lesioni premeanomatose. G. Minerva Dermatol. 112:167–171Google Scholar
- Hamid, Q., Bishop, A.E., Sikri, K.L., Varndell, I.M., Bloom, S.R., Polak, J.M. (1986) Immunocytochemical characteristion of 10 pancreatic tumours, associated with the glucagonoma syndrome, using antibodies to separate regions of the pro-glucagon molecule and other neuroendocrine markers. Histopathology 10:119–133PubMedCrossRefGoogle Scholar
- Hamid, Q.A., Wharton, J., Terenghi, G., Hassall, C., Aimi, J., Taylor, K.M., Nakazato, H., Dixon, J., Burnstock, G., Polak, J.M. (1987) Localization of atrial natriuretic peptide mRNA and immunoreactivity in rat heart and human atrial appendage. Proc. Natl. Acad. Sci. U.S.A. 84:6760–6764PubMedCrossRefGoogle Scholar
- NIH Consensus Development Conference Statement, October 24–26, Washington, D.C. (1984) Precursors to malignant melanoma. J. Am. Acad. Dermatol. 10:683–686Google Scholar
- Polak, J.M., Marangos, P.J. (1984) Neuron-specific enolase, a marker for neuroendocrine cells. Evolution and Tumour Pathology of the Neuroendocrine System. S. Falkmer, R. Hakanson, F. Sundler (eds). Elsevier, Amsterdam, pp 433–480Google Scholar
- Singer, R.H., Lawrence, J.B., Villnave, C. (1986) Optimization of in situ and non-isotopic detection methods. Biotechniques 4:230–250Google Scholar
- Sternberger, L.A. (1979) The unlabeled, antibody peroxidase-antiperoxidase (PAP) method. Immunocytochemistry. Wiley, New York, pp 104–169Google Scholar